Ocumension Therapeutics Company Description

Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China.

It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis.

The company was founded in 2017 and is based in Suzhou, the People's Republic of China.